Cognition Therapeutics Awarded $6.6M to Support 2 Elayta Trials for Alzheimer’s

Cognition Therapeutics Awarded $6.6M to Support 2 Elayta Trials for Alzheimer’s
Cognition Therapeutics has received two multi-year grants from the National Institute on Aging (NIA) totaling $6.6 million to fund two clinical studies of Elayta (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. Elayta is a brain-penetrating small molecule with a unique disease-modifying mechanism of action. The compound protects synapses — tiny connections

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *